Androxal (enclomiphene) stimulates the body's own production of testosterone by acting on the hypothalamic-pituitary axis, whereas conventional testosterone therapy supplies exogenous hormone, which can suppress natural production and affect fertility.
Enclomiphene is contraindicated in pregnancy and lactation and is not approved for any female indication. Its estrogen-receptor antagonism could interfere with normal hormonal balance in women.
Clinical studies have reported measurable increases in serum testosterone within 2-4 weeks of daily dosing, though individual response times vary.
Enclomiphene is not listed on the World Anti-Doping Agency (WADA) prohibited list, but athletes should verify with their governing bodies, as testing methods evolve.
Blurred or altered vision is a potential sign of retinal toxicity; the patient should stop the medication immediately and seek urgent ophthalmologic evaluation.
No specific foods must be avoided, but excessive alcohol consumption should be limited to reduce liver stress. A balanced diet supports overall hormone health.
Concurrent use of multiple SERMs is generally discouraged because overlapping mechanisms may increase the risk of adverse effects, especially on the visual and thrombotic systems.
Baseline liver enzymes are essential, followed by repeat testing after the first month and then every three months, or sooner if clinical signs of hepatic dysfunction appear.
Yes, provided the medication is kept in its original labelled container, accompanied by a copy of the prescribing information or clinical trial documentation to satisfy customs checks.
As an investigational product, Androxal is typically accessed through research programmes or specialist clinics, where cost structures differ from standard pharmacy pricing. Exact costs vary by centre and are not publicly disclosed.
Androxal is a brand-name medication that contains enclomiphene as its active ingredient. Enclomiphene belongs to the class of selective estrogen receptor modulators (SERMs) and is being studied as a hormone therapy for men with low testosterone levels (hypogonadism). In the United Kingdom, Androxal is not currently authorised by the MHRA for any indication; it remains an investigational product that may be accessed only within clinical trials or via special prescribing arrangements.
Enclomiphene acts primarily on the hypothalamic-pituitary-gonadal (HPG) axis:
The net effect is a rise in endogenous testosterone without the need for exogenous testosterone replacement. Onset of hormonal changes is typically observed within a few weeks of daily dosing, and the effect persists only while the medication is taken.
As of February 2026, Androxal has no approved indication in the UK. The MHRA has not granted marketing authorisation for any therapeutic indication. Enclomiphene is, however, under clinical investigation for:
Because the product is not approved, it should only be used within the context of a controlled clinical trial or a specialist-led compassionate use programme.
Enclomiphene has been explored in research settings for a few off-label purposes, all of which remain experimental:
Regulatory status: These uses are not approved by the MHRA or other regulatory bodies. Off-label use would require strict medical supervision, individualized risk assessment, and informed consent.
General advice: Patients should disclose all medicines, supplements, and herbal products to their prescribing clinician before starting Androxal.
Note: Because Androxal is investigational, exact dosing regimens should follow the protocol prescribed by the treating specialist or the clinical trial’s guideline.
This article provides educational information about Androxal and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
